Skip to content

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511378-60-00
Acronym
AOC 1001-CS3
Enrollment
39
Registered
2024-08-08
Start date
2024-12-11
Completion date
Unknown
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myotonic Dystrophy Type 1

Brief summary

Change from baseline to Week 30 in video Hand Opening Time (vHOT).

Detailed description

1. Change from baseline to Week 30 in: • Hand grip strength. • QMT total composite score. • DM1-ActivC., 2. Change from baseline to Week 30 in: • QMT upper extremity composite score. • QMT lower extremity composite score. • QMT individual muscle group scores. • 10MWRT. • PGI-S. • EQ-5D-5L., 3. Change from baseline to Week 54 in: • vHOT. • QMT composite and individual muscle group scores. • DM1-ActivC. • 10MWRT. • EQ-5D-5L. • PGI-S. PGI-C at Week 30 and Week 54.

Interventions

Sponsors

Avidity Biosciences Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
Change from baseline to Week 30 in video Hand Opening Time (vHOT).

Secondary

MeasureTime frame
1. Change from baseline to Week 30 in: • Hand grip strength. • QMT total composite score. • DM1-ActivC., 2. Change from baseline to Week 30 in: • QMT upper extremity composite score. • QMT lower extremity composite score. • QMT individual muscle group scores. • 10MWRT. • PGI-S. • EQ-5D-5L., 3. Change from baseline to Week 54 in: • vHOT. • QMT composite and individual muscle group scores. • DM1-ActivC. • 10MWRT. • EQ-5D-5L. • PGI-S. PGI-C at Week 30 and Week 54.

Countries

Denmark, France, Germany, Ireland, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026